First Biosimilar Zarxio (Filgrastim-sndz) Approved

Share this content:
The FDA has approved Zarxio (filgrastim-sndz), becoming the first biosimilar product approved in the U.S.
The FDA has approved Zarxio (filgrastim-sndz), becoming the first biosimilar product approved in the U.S.

The U.S. Food and Drug Administration has approved Zarxio (filgrastim-sndz), becoming the first biosimilar product approved in the United States.

Zarxio is biosimilar to Neupogen (filgrastim) and is approved for the same indications. Zarxio is indicated for patients with cancer receiving myelosuppressive chemotherapy, patients with acute myeloid leukemia (AML) receiving induction or consolidation chemotherapy, patients with cancer undergoing bone marrow transplantation, patients undergoing autologous peripheral blood progenitor cell collection therapy, and patients with severe chronic neutropenia. 

A biosimilar product must have the same mechanism(s) of action, route(s) of administration, dosage form(s) and strength(s) as the reference product and can only be approved by the FDA for the indication(s) and condition(s) of use that that have been approved for the reference product.

RELATED: Legal Challenges Begin for Biosimilar Agents

“Biosimilars will provide access to important therapies for patients who need them,” said FDA Commissioner Margaret A. Hamburg, M.D. “Patients and the health care community can be confident that biosimilar products approved by the FDA meet the agency's rigorous safety, efficacy and quality standards.”

The most common adverse events associated with treatment with Zarxio are muscle and bone aches and redness and itching or swelling at the injection site.

Serious adverse events include spleen rupture, serious allergic reactions, tachycardia, dyspnea, and tachypnea.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters